GILD

Gilead Sciences, Inc. Press Releases

$101.675
*  
0.395
0.39%
Get GILD Alerts
*Delayed - data as of Aug. 20, 2014 9:37 ET  -  Find a broker to begin trading GILD now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    GILD Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
7/25/2014 7:24:00 AM - Business Wire

Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries
7/24/2014 12:00:00 AM - Business Wire

Gilead Sciences Announces Second Quarter 2014 Financial Results
7/23/2014 4:05:00 PM - Business Wire

U.S. Food and Drug Administration Approves Gilead’s Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma
7/23/2014 11:48:00 AM - Business Wire

Gilead Sciences to Release Second Quarter 2014 Financial Results on Wednesday, July 23, 2014
7/16/2014 5:00:00 PM - Business Wire

Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Sofosbuvir for Chronic Hepatitis C
6/27/2014 3:01:00 AM - Business Wire

Biotechnology Equities Technical Notes -- Research on StemCells, Gilead Sciences, Galena Biopharma, and Inovio Pharma
6/26/2014 7:10:00 AM - PR Newswire

Gilead Sciences to Present at the Wells Fargo Healthcare Conference on Tuesday, June 17
6/16/2014 5:00:00 PM - Business Wire

Gilead Announces Phase 3 Data Showing That the Fixed-Dose Combination of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response (SVR12) Among Patients with Chronic Hepatitis C in Japan
6/15/2014 8:00:00 PM - Business Wire

Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, June 10
6/9/2014 5:00:00 PM - Business Wire

Gilead Announces Updated Phase 2 Results for Investigational GS-9973 in Relapsed Chronic Lymphocytic Leukemia
6/3/2014 8:30:00 AM - Business Wire

Stocks Coverage on Biotech Equities -- Research on Gilead Sciences, ARIAD Pharma, Rexahn Pharma, and Geron
5/30/2014 7:10:00 AM - PR Newswire